Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an update.
Telomir Pharmaceuticals, Inc. announced favorable results from its IND-enabling GLP toxicology and safety studies for Telomir-1 (Zn-Telomir) on December 17, 2025. The studies demonstrated that Telomir-1 was well tolerated with no treatment-related adverse effects, supporting its advancement to first-in-human clinical trials anticipated in 2026. The findings also bolster Telomir Pharmaceuticals’ positioning in oncology and age-related disease research, with ongoing preclinical studies and collaborations aimed at expanding its scientific and clinical impact.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the biotechnology and pharmaceutical industry, focusing on developing innovative therapeutics targeting oncology and age-related diseases. The company’s lead product, Telomir-1 (Zn-Telomir), is positioned in advanced clinical development stages with significant attention on addressing unmet medical needs in cancer treatment and aging-related conditions.
Average Trading Volume: 1,748,434
Technical Sentiment Signal: Sell
Current Market Cap: $48.13M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.